Conversation

4:06 pm ET *Immunic Reports That Its IMU-838 Has Demonstrated Preclinical Activity Against SARS-Coronavirus And Explores Plans For A Phase 2 Clinical Trial In Coronavirus Patients(Benzinga)
4
8